Gold is 2025’s best performer. UBS sees more upside
Kieran O’Kane, the Chief Commercial Officer of Biodesix Inc . (NASDAQ:BDSX), a company currently valued at $137 million, recently executed a series of stock transactions as reported in a recent SEC filing. According to InvestingPro analysis, the stock has faced significant headwinds, declining over 40% in the past six months. On February 11, O’Kane sold 17,527 shares of Biodesix common stock, generating a total of $16,198. The shares were sold at an average price of $0.9242, with transactions occurring at prices ranging from $0.90 to $0.9536. The current stock price sits near its 52-week low of $0.86, though InvestingPro data indicates the company maintains strong liquidity with a current ratio of 3.4x.
In addition to the stock sale, O’Kane acquired a significant number of shares through the exercise of restricted stock units (RSUs) on February 10. A total of 48,118 shares were acquired without any cash exchange. Following these transactions, O’Kane holds 128,039 shares in direct ownership. These transactions were part of routine financial activities related to covering tax obligations upon the vesting of RSUs. Want deeper insights? InvestingPro offers comprehensive analysis with 6+ additional ProTips and a detailed Fair Value assessment for Biodesix.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.